Last reviewed · How we verify

NCT05166824

Clinical Study To Assess The Safety, Parameters And Efficacy For Procedures Using A Radiofrequency Device

Completed NA Results posted Last updated 4 April 2022
What this trial tests

NA trial testing TempSure in Tissue Heating in 89 participants. Completed in 4 February 2019.

Timeline
18 January 2017
Primary endpoint
4 February 2019
4 February 2019

Quick facts

Lead sponsorCynosure, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment89
Start date18 January 2017
Primary completion4 February 2019
Estimated completion4 February 2019
Sites5 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cynosure, Inc. — full company profile →

Who can join

18 and older, any sex, with Tissue Heating or Coagulation. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Subject Satisfaction Primary · 30 days post final treatment

The subject will be asked their level of satisfaction using a 6-point Likert scale that ranges from "extremely satisfied" to "extremely unsatisfied," with 1 being extremely unsatisfied and 6 being extremely satisfied.

GroupValue95% CI
Women's Health0
Skin Rejuvenation6
Surgical- Blepharoplasty4
Women's Health2
Skin Rejuvenation14
Surgical- Blepharoplasty5
Women's Health4
Skin Rejuvenation11
Surgical- Blepharoplasty1
Women's Health2
Skin Rejuvenation1
Surgical- Blepharoplasty0
Number of Tissue Samples With Successful Results Primary · Immediately Post Treatment (Same Day)

This is the number of tissue samples removed by the device (on 1 subject) that has similar histological results to scalpels and cautery devices currently on the market.

GroupValue95% CI
Surgical- Abdominoplasty20

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse Events occurring were captured and followed through study completion, an average of 7 months. Subjects were instructed that they may contact the Investigator at any time throughout the course of the study.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Surgical- Abdominoplasty
Serious: 0/1 (0%)
Deaths: 0/1
Women's Health
Serious: 0/10 (0%)
Deaths: 0/10
Skin Rejuvenation
Serious: 0/68 (0%)
Deaths: 0/68
Surgical- Blepharoplasty
Serious: 0/10 (0%)
Deaths: 0/10
Other adverse events (10 terms — click to expand)

ReactionSystemSurgical- AbdominoplastyWomen's HealthSkin RejuvenationSurgical- Blepharoplasty
EdemaSkin and subcutaneous tissue disorders
ErythemaSkin and subcutaneous tissue disorders
ItchingSkin and subcutaneous tissue disorders
BruisiingRespiratory, thoracic and mediastinal disorders
BleedingSkin and subcutaneous tissue disorders
CrustingSkin and subcutaneous tissue disorders
HardnessSkin and subcutaneous tissue disorders
Skin BurnSkin and subcutaneous tissue disorders
InfectionInfections and infestations
BlisteringSkin and subcutaneous tissue disorders

Data from ClinicalTrials.gov NCT05166824 adverse events section.

Sponsor's own description

The purpose of this study was to develop parameters and assess the safety of the radiofrequency device for a variety of treatments. Treatment results were also evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of TempSure

Trials testing the same drug.

Other Cynosure, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05166824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing